HOME >> MEDICINE >> NEWS
Decline in breast cancer cases likely linked to reduced use of hormone replacement

SAN ANTONIO - In 2003, breast cancer incidence in the United States dropped sharply, and this decline may largely be due to the fact that millions of older women stopped using hormone replacement therapy (HRT) in 2002, according to a new analysis led by researchers at The University of Texas M. D. Anderson Cancer Center.

At the 29th annual San Antonio Breast Cancer Symposium, the investigators report that there was an overall 7 percent relative decline in breast cancer incidence between 2002 and 2003, and that the steepest decline - 12 percent - occurred in women between ages 50-69 diagnosed with estrogen receptor positive (ER-positive) breast cancer. This is the kind of breast cancer that is dependent on hormones for tumor growth.

From this, the researchers conclude that as many as 14,000 fewer women were diagnosed with breast cancer in 2003 than in 2002, a year in which the American Cancer Society estimates 203,500 new cases of breast cancer were diagnosed.

"It is the largest single drop in breast cancer incidence within a single year I am aware of," says Peter Ravdin, M.D., Ph.D., a research professor in the Department of Biostatistics at M. D. Anderson.

"Something went right in 2003, and it seems that it was the decrease in the use of hormone therapy, but from the data we used we can only indirectly infer that is the case," he says.

"But if it is true, the tumor growth effect of stopping use of HRT is very dramatic over a short period of time, making the difference between whether a tumor is detected on a mammogram in 2003 or not," says Ravdin.

The study's senior investigator, Donald Berry, Ph.D., professor and head of the Division of Quantitative Sciences at M. D. Anderson, says he was, at first, very surprised by both the magnitude and the rapidity of the decline in incidence, but adds "it makes perfect sense" if you consider that use of HRT may be an important contributing factor to breast cancer
'"/>

Contact: Scott Merville
sdmervil@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
14-Dec-2006


Page: 1 2 3

Related medicine news :

1. Declines in exercise capacity may be due to lack of training, not just age
2. Decline in breast cancer deaths explained by use of screening and adjuvant therapies
3. Decline in performance of candidates taking a postgraduate medical examination between 1997 and 2001
4. Decline in major heart disease offset by rise in diagnosed angina among British men
5. Survival differences by race most apparent in advanced stages of breast cancer
6. Regulator of lipid metabolism ensures high quality breast milk
7. MRI finds breast cancer before it becomes dangerous
8. New cause of tamoxifen resistance in breast cancer cells discovered at Lombardi
9. Pathway links inflammation, angiogenesis and breast cancer
10. Using MRI for diagnosis could help prevent breast cancer progression
11. Speeding up CT scans with cellphone technology, ultrasound warning signal for breast cancer

Post Your Comments:
(Date:5/21/2013)... (PRWEB) May 21, 2013 The ... to announce four transitions for its Board of Directors. ... the Western Michigan University School of Medicine, has been ... Medical Education at the University of California San Diego, ... Executive Officer of the Nebraska Medical Center, is the ...
(Date:5/21/2013)... Lapeer, MI (PRWEB) May 21, 2013 ... Support Group meeting in Lapeer on , June 11th. ... – 8:30pm, Location: Lapeer Regional Medical Center,     Conference Room ... 48446 , These meetings are designed to assist people ... connected with one another, and to get a better ...
(Date:5/21/2013)... The birth control safety advocates at DrugRisk.com ... the contraceptive NuvaRing. A new report shows the number ... increased in recent months*. , DrugRisk was created to ... the latest safety alerts, recalls, studies and legal news. ... side effects and decide if they need legal advice. ...
(Date:5/20/2013)... 21, 2013 USA Book News announced ... to Peak Performance" won the top honor in its ... Chosen over a multitude of international titles published from ... critical acclaim from both mainstream and new age audiences ... physically and spiritually. , “The Infinity Zone” ...
(Date:5/20/2013)... The automated external defibrillator market ... categories - semi-automated and fully automated defibrillators. Based ... categories, namely, hospitals, pre-hospital, public access, alternate care, ... Automated external defibrillators play an important role in ... Considering the life-saving potential of AEDs, legislations requiring ...
Breaking Medicine News(10 mins):Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 2Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 3Health News:DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3
(Date:5/20/2013)... 20, 2013  Atlantic Pharmaceuticals, Inc., a specialty ... a unique technology to deter prescription drug abuse ... Anthony Soscia , has been chosen ... Chronicle ,s Health-Care Heroes Awards. The awards are ... to honor individuals and organizations demonstrating excellence and ...
(Date:5/20/2013)... 20, 2013 Enrollment of patients with Type ... dose-finding clinical trial of product candidate NewMet ™, ... for Type 2 diabetes. Elcelyx expects to complete enrollment ... June. Results of the trial,s primary endpoint of change ... and the read-out for long-term glucose lowering and weight ...
(Date:5/20/2013)... -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that ... presented updated Phase I data from its spinal cord-derived ... of amyotrophic lateral sclerosis (ALS or Lou ... medical symposium in Bucharest, Romania , ... in Stem Cell Therapy," Dr. Feldman outlined the design ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
Cached News: